Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | PDE9A | O76083 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | PDE8A | O60658 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
| ▸ | PDE6A | P16499 | 1/20 | 0.41 |
| ▸ | PDE6G | P18545 | 1/20 | 0.41 |
| ▸ | PDE6B | P35913 | 1/20 | 0.41 |
| ▸ | PDE6C | P51160 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598766 | 0.92 | KDM4E (0.42) | PDE2APDE5APDE4APDE10APDE9A | |
| SCHEMBL3598874 | 0.88 | PDE9A (0.50) | PDE2APDE5APDE4APDE10APDE9A | |
| SCHEMBL3595669 | 0.83 | PDE9A (0.48) | PDE9AFGFR1SRCERCC1FEN1 | |
| SCHEMBL3591867 | 0.78 | PDE9A (0.56) | PDE5APDE10APDE9APDE1APDE1B | |
| SCHEMBL3591362 | 0.76 | PDE2A (0.46) | PDE2APDE5APDE4APDE10APDE9A | |
| SCHEMBL3595824 | 0.75 | PDE2A (0.53) | PDE2APDE5APDE4APDE10APDE9A | |
| SCHEMBL3595181 | 0.74 | PDE9A (0.49) | PDE5APDE9AALDH1A1KDM4EHPGD | |
| SCHEMBL3605996 | 0.73 | PDE9A (0.48) | PDE5APDE9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL972909 | 0.73 | ADORA3 (0.53) | PDE2APDE5APDE4APDE10APDE9A | |
| SCHEMBL3598272 | 0.71 | KDM4E (0.53) | PDE2APDE9AALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2489667-B1 | Quinoxaline derivative | ASKA PHARM CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | OKADA MAKOTO (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225572-A1 | Substituted Imidazo[1,5-A]Quinoxalines As a PDE9 Inhibitor | PDE9A, ADCY9, PDE3A | PDE2A 5/4885PDE5A 6/4885PDE4A 25/4885 |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE2A 4/4885PDE5A 8/4885PDE4A 36/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE2A 5/4885PDE5A 6/4885PDE4A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.